載入中
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
前收盤價
US$1.07
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
日內區間
目前US$1.07
52週區間
目前US$1.07
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
52
多空交錯
風險
64
高風險
動能
38
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
日內區間
目前US$1.07
52週區間
目前US$1.07
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4217.2萬 USD | 2.67億 USD | 2.57億 USD | 2.11億 USD | 3.27億 USD |
| 銷貨成本 | 1773.8萬 USD | 1.18億 USD | 1.59億 USD | 7008.3萬 USD | 5759.1萬 USD |
| 毛利 | 2443.4萬 USD | 1.49億 USD | 9825.2萬 USD | 1.41億 USD | 2.69億 USD |
| 研究與開發 | 1.05億 USD | 9333.6萬 USD | 1.09億 USD | 1.99億 USD | 3.63億 USD |
| 銷售、一般及管理費用 | 9900.4萬 USD | 1.5億 USD | 1.86億 USD | 1.98億 USD | 1.7億 USD |
| 營業費用 | 2.04億 USD | 2.61億 USD | 3.01億 USD | 3.98億 USD | 5.33億 USD |
| 利息支出 | 900.1萬 USD | 2715.8萬 USD | 4054.2萬 USD | 3247.4萬 USD | 2295.9萬 USD |
| 折舊和攤銷 | 392.4萬 USD | 527.6萬 USD | 379.1萬 USD | 369.9萬 USD | 345.4萬 USD |
| 營業利益 | −1.8億 USD | −1.12億 USD | −2.03億 USD | −2.57億 USD | −2.64億 USD |
| 淨利 | −1.7億 USD | 2850.7萬 USD | −2.38億 USD | −2.92億 USD | −2.87億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI533.74萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM355.88萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF241.94萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO101.12萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA74.96萬0.00%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO46.61萬0.00%139.17億 USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC41.23萬0.03%13.17億 USD0.60%US$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ21.99萬0.01%26.7億 USD0.36%US$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
